Image Credit: drmicrobe/123rf.com
A recent clinical trial published in the New England Journal of Medicine has reported promising results for a new drug, bepirovirsen, which has shown a functional cure rate of approximately 19% in patients with chronic hepatitis B. This is a significant improvement compared to the current standard of care, which achieves a functional cure in about 3% of patients over eight to ten years of treatment.
The B-Well trial, which involved 1,838 adults across 29 countries, assessed the efficacy of bepirovirsen through a six-month regimen of weekly injections, in conjunction with existing antiviral medications. Notably, among participants who received the drug, 26% of those with the lowest viral surface antigen levels at the study’s outset achieved the functional cure, meaning their immune systems managed to control the virus without medication for over six months.
Bepirovirsen functions by targeting the hepatitis B virus in two ways: it binds to viral messenger RNA to inhibit the production of viral proteins and is taken up by macrophages, which stimulates an immune response against the virus. This dual action positions bepirovirsen more as an immunomodulator rather than a conventional antiviral, enhancing the body’s natural defenses against hepatitis B.
Despite these positive developments, the trial had specific exclusions, omitting individuals with cirrhosis, severe disease, or HIV co-infection. The drug was most effective in patients who had better control of their hepatitis B prior to treatment, highlighting the importance of early diagnosis and regular monitoring.
Chronic hepatitis B affects over 240 million people globally, yet only 13% of those are aware of their condition. The virus can lead to severe liver complications, including cirrhosis and liver cancer, resulting in over one million deaths annually. Existing antiviral treatments can suppress the virus but rarely eliminate it, necessitating lifelong management.
Bepirovirsen’s trial results have been submitted to regulatory bodies in the United States, Canada, Europe, Japan, and China, with decisions on approval anticipated later this year. Potential side effects of the drug include changes in platelet counts and kidney function, as well as reactions at the injection site.
As the medical community looks forward to the potential approval of this innovative treatment, experts emphasize the need for increased efforts in diagnosing and connecting individuals with hepatitis B to appropriate care, aiming to combat the ongoing silent epidemic.
Check out the original article here: Source link
